Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial - The Lancet
Forest plot for toxicity indirect comparisons among combination... | Download Scientific Diagram
Cancers | Free Full-Text | Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome?
Pharmaceutics | Free Full-Text | A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC)
Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic can
Comparative Safety and Efficacy of Therapeutic Options in Resectable
Debate: Optimal therapy for patients with resectable pancreatic cancer - Surgery plus adjuvant chemo - YouTube
Gemcitabine (Gemzar®) - Pancreatic Cancer UK
Debate: Optimal adjuvant therapy for resected pancreatic cancer? - Gem/Nab-Paclitaxel or FOLFIRINOX - YouTube
2020 ASCO Pancreatic Cancer Highlights: Is Perioperative mFOLFIRINOX More Beneficial Than Gem/nab-P in Resectable Disease? Should Neoadjuvant Therapy Be Considered for Borderline Resectable Disease? | VuMedi
Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma - Sora Kang, Changhoon Yoo, So Heun Lee, Dongwook Oh, Tae Jun Song, Sang Soo Lee, Jae Ho
Comparative Safety and Efficacy of Therapeutic Options in Resectable and Advanced/Metastatic Pancreatic Cancer: A Systematic Review and Indirect Comparison | Semantic Scholar
JCM | Free Full-Text | Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients
![PDF] FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/390ed5d1b8c173153661b6f2dbb1028b07ac922d/7-Figure1-1.png "PDF] FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study | Semantic Scholar")
PDF] FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study | Semantic Scholar
Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic can
Figure 1 from FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. | Semantic Scholar
GTG on Twitter: "Ghaneh et al, phase 2 ESPAC-5F trial: Neoadjuvant therapy w/ GEMCAP, FOLFIRINOX or CRT did not increase resection rate over immediate surgery in borderline resectable pancreatic cancer, but significantly
Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic can
![PDF] FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/390ed5d1b8c173153661b6f2dbb1028b07ac922d/11-Table4-1.png "PDF] FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study | Semantic Scholar")
PDF] FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study | Semantic Scholar
The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. - Abstract - Europe PMC
